Literature DB >> 28031062

Maximizing the benefits of ART and PrEP in resource-limited settings.

G Akudibillah1, A Pandey2, J Medlock3.   

Abstract

Antiretroviral therapy (ART) is increasingly being used as an HIV-prevention tool, administered to uninfected people with ongoing HIV exposure as pre-exposure prophylaxis (PrEP) and to infected people to reduce their infectiousness. We used a modelling approach to determine the optimal population-level combination of ART and PrEP allocations required in South Africa to maximize programme effectiveness for four outcome measures: new infections, infection-years, death and cost. We considered two different strategies for allocating treatment, one that selectively allocates drugs to sex workers and one that does not. We found that for low treatment availability, prevention through PrEP to the general population or PrEP and ART to sex workers is key to maximizing effectiveness, while for higher drug availability, ART to the general population is optimal. At South Africa's current level of treatment availability, using prevention is most effective at reducing new infections, infection-years, and cost, while using the treatment as ART to the general population best reduces deaths. At treatment levels that meet the UNAIDS's ambitious new 90-90-90 target, using all or almost all treatment as ART to the general population best reduces all four outcome measures considered.

Entities:  

Keywords:  ART; HIV/AIDS; PrEP; mathematical modelling; optimization

Mesh:

Substances:

Year:  2016        PMID: 28031062      PMCID: PMC5861504          DOI: 10.1017/S0950268816002958

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  24 in total

1.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

Authors:  R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

Review 3.  The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Authors:  Julio S G Montaner; Robert Hogg; Evan Wood; Thomas Kerr; Mark Tyndall; Adrian R Levy; P Richard Harrigan
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

4.  Ten myths and one truth about generalised HIV epidemics.

Authors:  James D Shelton
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

5.  Can antiretroviral therapy eliminate HIV transmission?

Authors:  Kevin M De Cock; Charles F Gilks; Ying-Ru Lo; Teguest Guerma
Journal:  Lancet       Date:  2008-11-27       Impact factor: 79.321

6.  Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy.

Authors:  Norbert Bräu; Mirella Salvatore; Carlos F Ríos-Bedoya; Alberto Fernández-Carbia; Fiorenzo Paronetto; José F Rodríguez-Orengo; Maribel Rodríguez-Torres
Journal:  J Hepatol       Date:  2005-07-27       Impact factor: 25.083

7.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

8.  Modelling progression of CD4-lymphocyte count and its relationship to survival time.

Authors:  V De Gruttola; X M Tu
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

9.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

10.  Decline in the prevalence of HIV and sexually transmitted diseases among female sex workers in Cotonou, Benin, 1993-1999.

Authors:  Michel Alary; Léonard Mukenge-Tshibaka; France Bernier; Nassirou Geraldo; Catherine M Lowndes; Honoré Meda; Cyriaque A B Gnintoungbè; Séverin Anagonou; Jean R Joly
Journal:  AIDS       Date:  2002-02-15       Impact factor: 4.177

View more
  3 in total

1.  The per-patient costs of HIV services in South Africa: Systematic review and application in the South African HIV Investment Case.

Authors:  Gesine Meyer-Rath; Craig van Rensburg; Calvin Chiu; Rahma Leuner; Lise Jamieson; Steve Cohen
Journal:  PLoS One       Date:  2019-02-26       Impact factor: 3.240

Review 2.  The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward.

Authors:  Kelsey K Case; Gabriela B Gomez; Timothy B Hallett
Journal:  J Int AIDS Soc       Date:  2019-09       Impact factor: 5.396

3.  PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention.

Authors:  Kenneth H Mayer; Lao-Tzu Allan-Blitz
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-01       Impact factor: 3.731

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.